This product is a linearized polyethyleneimine (Polyethylenimine Linear, PEI) specially developed for the large-scale production of AAV in suspension culture systems. It is a chemically synthesized product, free of animal-derived components, with low cytotoxicity. The product is provided in sterile liquid form and has a wide applicability for various AAV serotypes. It features strong DNA loading capacity, low transfection complex ratio, and high complex stability, facilitating large-scale AAV and protein production. Features Optimized for AAV Manufacturing: Specially developed for large-scale recombinant AAV production in suspension 293 cell lines. Superior Packaging Efficiency: Achieves a doubled full capsid ratio with 10× higher efficiency compared to standard PEI. Reduced Reagent Usage: Delivers equivalent transfection efficiency with just 1/4 the amount of PEI, cutting reagent input in half. Cost-Effective: Lower consumption directly reduces overall production cost. High Transfection Performance: Ensures robust and reliable transfection across a wide range of applications. Regulatory Advantage: GMP-ready with DMF filing support, accelerating project approval and commercialization. Applications Production of AAV/LV Viral Vectors Protein production Specifications Form liquid Properties Polyethylenimine Linear (PEI) Virus Type AAV Components Components No. Name 40823ES01 40823ES03 40823ES10 40823ES60 40823 Hieff Trans™ UltraAAV Transfection Reagent 100 μL 1 mL 10 mL 100 mL Shipping and Storage Hieff Trans™ UltraAAV Transfection Reagent products should be stored at 2-8℃ for 2 year. Figures 1. Cost-Efficient & Minimal Reagent Use Figure 1. Hieff Trans™ UltraAAV achieves more with less—minimizing reagent input while maximizing protein production efficiency. 2. High-efficiency transfection Figure 2. Comparison of transfection performance between Yeasen Hieff TransTM (PEI AAV) and Control PEI(FectorVIR-AAV). Hieff TransTM requires only half the reagent input yet still achieves higher viral yield than Control PEI. At equivalent viral production, the cost of transfection reagent is reduced by 50%. 3. Maximized AAV Yield Figure 3. Hieff Trans™ UltraAAV maximizes AAV yield across multiple serotypes. Superior transfection efficiency was observed compared with leading PEIs. AAV2, AAV5, AAV8, and AAV9 were produced in suspension 293F cells using 1 µg DNA per million cells. Viral particles were harvested 72 hours post-transfection, and supernatants were analyzed. 4. Strong Stability Figure 4. Stability evaluation in the AAV9 project. Hieff TransTM demonstrated consistent performance across three GMP-grade batches and passed both accelerated and transport stability testing, ensuring reliable and stable supply. Related Reading Revolutionary PEI-Mediated Gene Delivery for Superior Transfection Efficiency Documents: Safety Data Sheet 40823_MSDS_HB250211 Manuals 40823_Manual_Ver.EN20250513
Related
Related